BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics and pharmacodynamics of warfarin at steady state. 1979

P A Routledge, and P H Chapman, and D M Davies, and M D Rawlins

1 The relationship between warfarin dose, total and free plasma warfarin concentration, and anticoagulant effect was examined at several steady-state levels in fifteen patients during withdrawal of warfarin therapy. 2 Total plasma clearance was significantly correlated with the free fraction in plasma (r=0.955). 3 There was an age related decline in the dose of warfarin, and in the total and free plasma warfarin concentrations required to produce the same anticoagulant effect. However, neither total nor free plasma warfarin clearances varied with age. 4 Individual patients' log concentration-effect relationships were linear above a prothrombin ratio of 1.2 and there was a significant correlation (r=-0.586) between the slope and the free fraction of warfarin in plasma. It is suggested that plasma protein binding may reflect the interaction between warfarin and its effector site in the hepatocyte.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011517 Prothrombin Time Clotting time of PLASMA recalcified in the presence of excess TISSUE THROMBOPLASTIN. Factors measured are FIBRINOGEN; PROTHROMBIN; FACTOR V; FACTOR VII; and FACTOR X. It is used for monitoring anticoagulant therapy with COUMARINS. Quick Test,Russell's Viper Venom Time,Thrombotest,Russell Viper Venom Time,Russells Viper Venom Time,Prothrombin Times,Test, Quick,Time, Prothrombin,Times, Prothrombin
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect
D014859 Warfarin An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide. 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one,Aldocumar,Apo-Warfarin,Coumadin,Coumadine,Gen-Warfarin,Marevan,Tedicumar,Warfant,Warfarin Potassium,Warfarin Sodium,Potassium, Warfarin,Sodium, Warfarin

Related Publications

P A Routledge, and P H Chapman, and D M Davies, and M D Rawlins
Pharmacodynamics of warfarin at steady state.
January 1987, Therapeutic drug monitoring,
P A Routledge, and P H Chapman, and D M Davies, and M D Rawlins
Irbesartan does not affect the steady-state pharmacodynamics and pharmacokinetics of warfarin.
October 1999, European journal of clinical pharmacology,
P A Routledge, and P H Chapman, and D M Davies, and M D Rawlins
Effects of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady state in healthy subjects.
December 2009, Journal of clinical pharmacology,
P A Routledge, and P H Chapman, and D M Davies, and M D Rawlins
Pharmacokinetics and pharmacodynamics of nifedipine in patients at steady state.
January 1986, Journal of clinical pharmacology,
P A Routledge, and P H Chapman, and D M Davies, and M D Rawlins
The effect of diflunisal on the steady state pharmacodynamics and pharmacokinetics of warfarin [proceedings].
March 1980, British journal of clinical pharmacology,
P A Routledge, and P H Chapman, and D M Davies, and M D Rawlins
Propranolol pharmacokinetics and pharmacodynamics after single doses and at steady-state.
January 1987, European journal of clinical pharmacology,
P A Routledge, and P H Chapman, and D M Davies, and M D Rawlins
The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans.
July 1999, European journal of clinical pharmacology,
P A Routledge, and P H Chapman, and D M Davies, and M D Rawlins
Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state.
October 2004, Antimicrobial agents and chemotherapy,
P A Routledge, and P H Chapman, and D M Davies, and M D Rawlins
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
February 2009, Antimicrobial agents and chemotherapy,
P A Routledge, and P H Chapman, and D M Davies, and M D Rawlins
Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin.
May 2002, British journal of clinical pharmacology,
Copied contents to your clipboard!